EFFICACY OF TERIPARATIDE ON OSTEOPOROSIS IN PATIENTS WITH RHEUMATOID ARTHRITIS ∼IS IT APPROPRIATE TO PRESCRIBE TERIPARATIDE TOGETHER WITH BIOLOGICAL AGENTS?

被引：0
|
作者：
Hirano, Y. [1 ]
Oishi, Y. [1 ]
Takemoto, G. [1 ]
Kojima, T. [2 ]
Ishiguro, N. [2 ]
机构：
[1] Toyohashi Municipal Hosp, Toyohashi, Aichi, Japan
[2] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [31] THE COMPARATION OF EFFICACY OF TREATMENT WITH TERIPARATIDE IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS AND GLUCOCORTICOID INDUCED OSTEOPOROSIS IN COMMON POPULATION
    Ruzickova, O. R.
    Tomasova, J. T.
    Sokalska, M. S.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S481 - S483
  • [32] Characteristics of patients initiating teriparatide for the treatment of osteoporosis
    Foster, S. A.
    Foley, K. A.
    Meadows, E. S.
    Johnston, J. A.
    Wang, S.
    Pohl, G. M.
    Long, S. R.
    OSTEOPOROSIS INTERNATIONAL, 2008, 19 (03) : 373 - 377
  • [33] Teriparatide in patients with osteoporosis and type 2 diabetes
    Schwartz, Ann V.
    Pavo, Imre
    Alam, Jahangir
    Disch, Damon P.
    Schuster, Dara
    Harris, Jennifer M.
    Krege, John H.
    BONE, 2016, 91 : 152 - 158
  • [34] Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy
    Nasomyont, N.
    Keefe, C.
    Tian, C.
    Hornung, L.
    Khoury, J.
    Tilden, J.
    Hochwalt, P.
    Jackson, E.
    Rybalsky, I.
    Wong, B.
    Rutter, M.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S132 - S132
  • [35] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S59 - S60
  • [36] Characteristics of patients initiating teriparatide for the treatment of osteoporosis
    S. A. Foster
    K. A. Foley
    E. S. Meadows
    J. A. Johnston
    S. Wang
    G. M. Pohl
    S. R. Long
    Osteoporosis International, 2008, 19 : 373 - 377
  • [37] Efficacy of adding teriparatide versus switching to teriparatide in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate
    Cosman, F.
    Wermers, R. A.
    Recknor, C.
    Mauck, K. F.
    Xie, L.
    Glass, E. V.
    Krege, J. H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S89 - S89
  • [38] Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy
    Nasomyont, N.
    Keefe, C.
    Tian, C.
    Hornung, L.
    Khoury, J.
    Tilden, J. C.
    Hochwalt, P.
    Jackson, E.
    Rybalsky, I
    Wong, B. L.
    Rutter, Meilan M.
    OSTEOPOROSIS INTERNATIONAL, 2020, 31 (12) : 2449 - 2459
  • [39] Assessment of the Effects of Switching Bisphosphonates to Denosumab or Daily Teriparatide in Patients with Rheumatoid Arthritis
    Ebina, Kosuke
    Hirao, Makoto
    Hashimoto, Jun
    Yukioka, Masao
    Noguchi, Takaaki
    Yoshikawa, Hideki
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [40] Undercarboxylated osteocalcin may be an attractive marker of teriparatide treatment in rheumatoid arthritis patients
    S. Mokuda
    Osteoporosis International, 2015, 26 : 1443 - 1443
12345